Closed · opens Mon 9:30 AM ET
The Marked Chart Wire · Health
Cancer Vaccines
Merck and Moderna said their personalized cancer vaccine cut the risk of melanoma recurrence or death by 42 percent in a Phase III trial. The combination showed a favorable survival trend with no new safety signals.
Cancer Vaccine
The two companies disclosed late-stage clinical findings for their mRNA therapy, intismeran autogene, after an information leak occurred.
Moderna
Moderna stock fell about 25 percent after Phase III melanoma vaccine results reportedly leaked online. The data showed a 42 percent reduction in recurrence or death risk, a weaker result than earlier trials.
CRISPR Therapeutics
CRISPR Therapeutics' pipeline candidate CTX310 is viewed as having a larger market opportunity than its approved product Casgevy.
Nubeqa
Orion Corporation stated that adding Nubeqa to standard care significantly lowered the chance of disease spread or mortality in high-risk patients.
Lung Cancer
Amgen reported that adding its medication to AstraZeneca’s immunotherapy reduced the chance of death by 58 percent for individuals with advanced lung tumors.
AbbVie
The FDA approved an injectable version of AbbVie's Skyrizi to treat moderate to severe Crohn's disease.
Fast headlines, summarized. Not verified and not advice. Check the full story before you act.